Clinical Trials Logo

Dyskinesias clinical trials

View clinical trials related to Dyskinesias.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01804920 Active, not recruiting - Tardive Dyskinesia Clinical Trials

D-Serine Treatment For Tardive Dyskinesia

Start date: January 2013
Phase: N/A
Study type: Interventional

Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which are caused by treatment with presently used antipsychotics drugs. The hypothesis under investigation in the present study is that D-serine adjuvant treatment may improve TD in schizophrenia patients diagnosed with this disorder.

NCT ID: NCT00291733 Active, not recruiting - Clinical trials for Levodopa Induced Dyskinesia

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Levodopa-induced dyskinesias have been associated with irregular oscillatory discharge characteristics of basal ganglia. From the other hand, LEV which shares a different electrophysiologic profile than other antiepileptics, inhibits hyper-synchronization of abnormal neuronal firing in experimental models of epilepsy. LEV also reduces levodopa-induced dyskinesias in MPTP-lesioned macaques and modulates "priming phenomenon" which associated with long-term changes in synaptic function that can lead to dyskinesias in PD. Study objectives : - To evaluate the effects of levetiracetam (LEV) in two doses (500 and 1000mg) vs placebo on disabling dyskinesias that develop as result of long-term treatment with levodopa, occurring at the time of maximal clinical improvement in patients with Parkinson's disease (PD). - To evaluate the safety of LEV in patients with PD and antiparkinsonian medication.